"Canonical and non-canonical actions of GRK5 in the heart"

Journal of Molecular and Cellular Cardiology

Volumn 92, Issue , 2016, Pages 196-202

  Traynham, Christopher J ^a   Hullmann, Jonathan ^b   Koch, Walter J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

G protein coupled receptor; Heart failure; Hypertrophy; Myocardium

Indexed keywords

G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 5; GRK5 PROTEIN, HUMAN;

CELL NUCLEUS; ENZYME ACTIVITY; ENZYME LOCALIZATION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; CARDIAC MUSCLE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

G-PROTEIN-COUPLED RECEPTOR KINASE 5; HEART FAILURE; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIUM;

EID: 84958953761     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.01.027     Document Type: Review

References (82)

1. Arunlakshana O., Schild H.O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. Chemother. 1959, 14:48-58.
2. Lefkowitz R.J. Seven transmembrane receptors: something old, something new. Acta Physiol (Oxf.) 2007, 190:9-19.
3. Katritch V., Cherezov V., Stevens R.C. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 2013, 53:531-556.
4. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat. Rev. Drug Discov. 2006, 5:993-996.
5. Pierce K.L., Lefkowitz R.J. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2001, 2:727-733.
6. Pitcher J.A., Freedman N.J., Lefkowitz R.J. G protein-coupled receptor kinases. Annu. Rev. Biochem. 1998, 67:653-692.
7. Premont R.T., Gainetdinov R.R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 2007, 69:511-534.
8. Drake M.T., Shenoy S.K., Lefkowitz R.J. Trafficking of G protein-coupled receptors. Circ. Res. 2006, 99:570-582.
9. Gainetdinov R.R., Bohn L.M., Walker J.K., Laporte S.A., Macrae A.D., Caron M.G., et al. Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. Neuron 1999, 24:1029-1036.
10. Pearce L.R., Komander D., Alessi D.R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 2010, 11:9-22.
11. Homan K.T., Tesmer J.J. Structural insights into G protein-coupled receptor kinase function. Curr. Opin. Cell Biol. 2014, 27C:25-31.
12. Huang Z.M., Gold J.I., Koch W.J. G protein-coupled receptor kinases in normal and failing myocardium. Front Biosci 2011, 16:3047-3060. Landmark Ed.
13. Pitcher J.A., Fredericks Z.L., Stone W.C., Premont R.T., Stoffel R.H., Koch W.J., et al. Phosphatidylinositol 4,5-bisphosphate (PIP2)-enhanced G protein-coupled receptor kinase (GRK) activity. Location, structure, and regulation of the PIP2 binding site distinguishes the GRK subfamilies. J. Biol. Chem. 1996, 271:24907-24913.
14. Gurevich E.V., Tesmer J.J., Mushegian A., Gurevich V.V. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol. Ther. 2012, 133:40-69.
15. Thiyagarajan M.M., Stracquatanio R.P., Pronin A.N., Evanko D.S., Benovic J.L., Wedegaertner P.B. A predicted amphipathic helix mediates plasma membrane localization of GRK5. J. Biol. Chem. 2004, 279:17989-17995.
16. Ding B., Glukhova A., Sobczyk-Kojiro K., Mosberg H.I., Tesmer J.J., Chen Z. Unveiling the membrane-binding properties of N-terminal and C-terminal regions of G protein-coupled receptor kinase 5 by combined optical spectroscopies. Langmuir 2013, 30:823-831.
17. Yang P., Glukhova A., Tesmer J.J., Chen Z. Membrane orientation and binding determinants of G protein-coupled receptor kinase 5 as assessed by combined vibrational spectroscopic studies. PLoS ONE 2013, 8.
18. Penn R.B., Pronin A.N., Benovic J.L. Regulation of G protein-coupled receptor kinases. Trends Cardiovasc. Med. 2000, 10:81-89.
19. Chen C.K., Inglese J., Lefkowitz R.J., Hurley J.B. Ca(2+)-dependent interaction of recoverin with rhodopsin kinase. J. Biol. Chem. 1995, 270:18060-18066.
20. Pronin A.N., Satpaev D.K., Slepak V.Z., Benovic J.L. Regulation of G protein-coupled receptor kinases by calmodulin and localization of the calmodulin binding domain. J. Biol. Chem. 1997, 272:18273-18280.
21. Levay K., Satpaev D.K., Pronin A.N., Benovic J.L., Slepak V.Z. Localization of the sites for Ca2+-binding proteins on G protein-coupled receptor kinases. Biochemistry 1998, 37:13650-13659.
22. Pronin A.N., Morris A.J., Surguchov A., Benovic J.L. Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 2000, 275:26515-26522.
23. Gold J.I., Martini J.S., Hullmann J., Gao E., Chuprun J.K., Lee L., et al. Nuclear translocation of cardiac G protein-coupled receptor kinase 5 downstream of select Gq-activating hypertrophic ligands is a calmodulin-dependent process. PLoS ONE 2013, 8.
24. Yi X.P., Gerdes A.M., Li F. Myocyte redistribution of GRK2 and GRK5 in hypertensive, heart-failure-prone rats. Hypertension 2002, 39:1058-1063.
25. Johnson L.R., Scott M.G., Pitcher J.A. G protein-coupled receptor kinase 5 contains a DNA-binding nuclear localization sequence. Mol. Cell. Biol. 2004, 24:10169-10179.
26. Johnson L.R., Robinson J.D., Lester K.N., Pitcher J.A. Distinct structural features of G protein-coupled receptor kinase 5 (GRK5) regulate its nuclear localization and DNA-binding ability. PLoS ONE 2013, 8.
27. Liu P., Wang X., Gao N., Zhu H., Dai X., Xu Y., et al. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression. Brain Res. 2010, 1307:134-141.
28. Lodowski D.T., Tesmer V.M., Benovic J.L., Tesmer J.J. The structure of G protein-coupled receptor kinase (GRK)-6 defines a second lineage of GRKs. J. Biol. Chem. 2006, 281:16785-16793.
29. GW Dorn GRK mythology: G-protein receptor kinases in cardiovascular disease. J Mol Med 2009, 87:455-463. Berl.
30. Kunapuli P., Benovic J.L. Cloning and expression of GRK5: a member of the G protein-coupled receptor kinase family. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5588-5592.
31. Premont R.T., Koch W.J., Inglese J., Lefkowitz R.J. Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J. Biol. Chem. 1994, 269:6832-6841.
32. Jaber M., Koch W.J., Rockman H., Smith B., Bond R.A., Sulik K.K., et al. Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:12974-12979.
33. Burkhalter M.D., Fralish G.B., Premont R.T., Caron M.G., Philipp M. Grk5l controls heart development by limiting mTOR signaling during symmetry breaking. Cell Rep. 2013, 4:625-632.
34. Philipp M., Berger I.M., Just S., Caron M.G. Overlapping and opposing functions of G protein-coupled receptor kinase 2 (GRK2) and GRK5 during heart development. J. Biol. Chem. 2014, 289:26119-26130.
35. Rockman H.A., Choi D.J., Rahman N.U., Akhter S.A., Lefkowitz R.J., Koch W.J. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9954-9959.
36. Martini J.S., Raake P., Vinge L.E., DeGeorge B.R., Chuprun J.K., Harris D.M., et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:12457-12462.
37. Akhter S.A., Luttrell L.M., Rockman H.A., Iaccarino G., Lefkowitz R.J., Koch W.J. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998, 280:574-577.
38. Yi X.P., Zhou J., Baker J., Wang X., Gerdes A.M., Li F. Myocardial expression and redistribution of GRKs in hypertensive hypertrophy and failure. Anat. Rec. A: Discov. Mol. Cell. Evol. Biol. 2005, 282:13-23.
39. Zhang Y., Matkovich S.J., Duan X., Gold J.I., Koch W.J., Dorn G.W. Nuclear effects of G-protein receptor kinase 5 on histone deacetylase 5-regulated gene transcription in heart failure. Circ. Heart Fail. 2011, 4:659-668.
40. Gold J.I., Gao E., Shang X., Premont R.T., Koch W.J. Determining the absolute requirement of G protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication. Circ. Res. 2013, 111:1048-1053.
41. Liggett S.B., Cresci S., Kelly R.J., Syed F.M., Matkovich S.J., Hahn H.S., et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat. Med. 2008, 14:510-517.
42. Figtree G.A., Bagnall R.D., Abdulla I., Buchholz S., Galougahi K.K., Yan W., et al. No association of G-protein-coupled receptor kinase 5 or beta-adrenergic receptor polymorphisms with Takotsubo cardiomyopathy in a large Australian cohort. Eur. J. Heart Fail. 2013, 15:730-733.
43. Kang S., Hong X., Ruan C.W., Yu P., Yu S.S., Chen M., et al. Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure. J. Transl. Med. 2015, 13(44). 10.1186/s12967-015-0402-7.
44. Spinelli L., Trimarco V., Di Marino S., Marino M., Iaccarino G., Trimarco B. L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome. Eur. J. Heart Fail. 2010, (12):13-16. 10.1093/eurjhf/hfp173.
45. Eijgelsheim M., Visser L.E., Uitterlinden A.G., Stricker B.H. Protective effect of a GRK5 polymorphism on heart failure and its interaction with beta-adrenergic receptor antagonists. Pharmacogenomics 2008, 9:1551-1555.
46. Kurnik D., Cunningham A.J., Sofowora G.G., Kohli U., Li C., Friedman E.A., et al. GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics 2009, 10:1581-1587.
47. Dzimiri N., Muiya P., Andres E., Al-Halees Z. Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. Eur. J. Pharmacol. 2004, 489:167-177.
48. Dzimiri N., Basco C., Moorji A., Afrane B., Al-Halees Z. Characterization of lymphocyte beta 2-adrenoceptor signalling in patients with left ventricular volume overload disease. Clin. Exp. Pharmacol. Physiol. 2002, 29:181-188.
49. Monto F., Oliver E., Vicente D., Rueda J., Aguero J., Almenar L., et al. Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure etiology and correlates to clinical variables. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H368-H376.
50. Aguero J., Almenar L., Monto F., Oliver E., Sanchez-Lazaro I., Vicente D., et al. Myocardial G protein receptor-coupled kinase expression correlates with functional parameters and clinical severity in advanced heart failure. J. Card. Fail. 2012, 18:53-61.
51. Aguero J., Almenar L., D'Ocon P., Oliver E., Monto F., Moro J., et al. Correlation between beta-adrenoceptors and G-protein-coupled receptor kinases in pretransplantation heart failure. Transplant. Proc. 2008, 40:3014-3016.
52. Aguero J., Almenar L., D'Ocon P., Oliver E., Monto F., Rueda J., et al. Myocardial and peripheral lymphocytic transcriptomic dissociation of beta-adrenoceptors and G protein-coupled receptor kinases in heart transplantation. J. Heart Lung Transplant. 2009, 28:1166-1171.
53. Keys J.R., Zhou R.H., Harris D.M., Druckman C.A., Eckhart A.D. Vascular smooth muscle overexpression of G protein-coupled receptor kinase 5 elevates blood pressure, which segregates with sex and is dependent on Gi-mediated signaling. Circulation 2005, 112:1145-1153.
54. Wu J.H., Zhang L., Fanaroff A.C., Cai X., Sharma K.C., Brian L., et al. G protein-coupled receptor kinase-5 attenuates atherosclerosis by regulating receptor tyrosine kinases and 7-transmembrane receptors. Arterioscler. Thromb. Vasc. Biol. 2012, 32:308-316.
55. Hullmann J.E., Grisanti L.A., Makarewich C.A., Gao E., Gold J.I., Chuprun J.K., et al. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ. Res. 2014, 20:304475.
56. Parameswaran N., Pao C.S., Leonhard K.S., Kang D.S., Kratz M., Ley S.C., et al. Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages. J. Biol. Chem. 2006, 281:34159-34170.
57. Patial S., Saini Y., Parvataneni S., Appledorn D.M., Dorn G.W., Lapres J.J., et al. Myeloid-specific GPCR kinase-2 negatively regulates NF-kappaB1p105-ERK pathway and limits endotoxemic shock in mice. J. Cell. Physiol. 2011, 226:627-637.
58. Patial S., Luo J., Porter K.J., Benovic J.L., Parameswaran N. G-protein-coupled-receptor kinases mediate TNFalpha-induced NFkappaB signalling via direct interaction with and phosphorylation of IkappaBalpha. Biochem. J. 2010, 425:169-178.
59. Patial S., Shahi S., Saini Y., Lee T., Packiriswamy N., Appledorn D.M., et al. G-protein coupled receptor kinase 5 mediates lipopolysaccharide-induced NFkappaB activation in primary macrophages and modulates inflammation in vivo in mice. J. Cell. Physiol. 2011, 226:1323-1333.
60. Valanne S., Myllymaki H., Kallio J., Schmid M.R., Kleino A., Murumagi A., et al. Genome-wide RNA interference in Drosophila cells identifies G protein-coupled receptor kinase 2 as a conserved regulator of NF-kappaB signaling. J. Immunol. 2010, 184:6188-6198.
61. Islam K.N., Bae J.W., Gao E., Koch W.J. Regulation of nuclear factor kappaB (NF-kappaB) in the nucleus of cardiomyocytes by G protein-coupled receptor kinase 5 (GRK5). J. Biol. Chem. 2013, 288:35683-35689.
62. Sorriento D., Ciccarelli M., Santulli G., Campanile A., Altobelli G.G., Cimini V., et al. The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17818-17823.
63. Islam K.N., Koch W.J. Involvement of nuclear factor kappaB (NF-kappaB) signaling pathway in regulation of cardiac G protein-coupled receptor kinase 5 (GRK5) expression. J. Biol. Chem. 2012, 287:12771-12778.
64. Noma T., Lemaire A., Naga Prasad S.V., Barki-Harrington L., Tilley D.G., Chen J., et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 2007, 117:2445-2458.
65. van Berlo J.H., Maillet M., Molkentin J.D. Signaling effectors underlying pathologic growth and remodeling of the heart. J. Clin. Invest. 2013, 123:37-45.
66. Huang C.Y., Yang A.L., Lin Y.M., Wu F.N., Lin J.A., Chan Y.S., et al. Anti-Apoptotic and Pro-Survival Effects of Exercise Training on Hypertensive Hearts. 1985 2012, 112:883-891.
67. Wilkins B.J., Dai Y.S., Bueno OF, Parsons S.A., Xu J., Plank D.M., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 2004, 94:110-118.
68. Wang Y., Wisloff U., Kemi O.J. Animal models in the study of exercise-induced cardiac hypertrophy. Physiol. Res. 2010, 59:633-644.
69. Traynham C.J., Cannavo A., Zhou Y., Vouga A., Woodall B.P., Hullmann J.E., et al. Differential role of G protein-coupled receptor kinase 5 in physiological versus pathological cardiac hypertrophy. Circ. Res. 2015, 29:306961.
70. Akhter S.A., Luttrell L.M., Rockman H.A., Iaccarino G., Lefkowitz R.J., Koch W.J. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998, 280:574-577.
71. Ibarra C., Estrada M., Carrasco L., Chiong M., Liberona J.L., Cardenas C., et al. Insulin-like growth factor-1 induces an inositol 1,4,5-trisphosphate-dependent increase in nuclear and cytosolic calcium in cultured rat cardiac myocytes. J. Biol. Chem. 2004, 279:7554-7565.
72. McMullen J.R., Shioi T., Huang W.Y., Zhang L., Tarnavski O., Bisping E., et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J. Biol. Chem. 2004, 279:4782-4793.
73. McMullen J.R., Amirahmadi F., Woodcock E.A., Schinke-Braun M., Bouwman R.D., Hewitt K.A., et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:612-617.
74. Budiono B.P., See Hoe L.E., Peart J.N., Sabapathy S., Ashton K.J., Haseler L.J., et al. Voluntary running in mice beneficially modulates myocardial ischemic tolerance, signaling kinases, and gene expression patterns. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302:R1091-R1100.
75. Konhilas J.P., Watson P.A., Maass A., Boucek D.M., Horn T., Stauffer B.L., et al. Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ. Res. 2006, 98:540-548.
76. Moreira-Goncalves D., Henriques-Coelho T., Fonseca H., Ferreira R.M., Amado F., Leite-Moreira A., et al. Moderate exercise training provides left ventricular tolerance to acute pressure overload. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1044-H1052.
77. Homan K.T., Larimore K.M., Elkins J.M., Szklarz M., Knapp S., Tesmer J.J. Identification and structure-function analysis of subfamily selective g protein-coupled receptor kinase inhibitors. ACS Chem. Biol. 2015, 10:310-319.
78. Schumacher-Bass S.M., Traynham C.J., Koch W.J. G protein-coupled receptor kinase 2 as a therapeutic target for heart failure. Drug Discov. Today Ther Strateg. 2012, 9. e155-e62.
79. Schumacher S.M., Gao E., Zhu W., Chen X., Chuprun J.K., Feldman A.M., et al. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci. Transl. Med. 2015, 7. 277ra31.
80. Homan K.T., Wu E., Cannavo A., Koch W.J., Tesmer J.J. Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor. Molecules 2014, 19:16937-16949.
81. Chen M., Sato P.Y., Chuprun J.K., Peroutka R.J., Otis N.J., Ibetti J., et al. Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting. Circ. Res. 2013, 112:1121-1134.
82. Sato P.Y., Chuprun J.K., Ibetti J., Cannavo A., Drosatos K., Elrod J.W., et al. GRK2 compromises cardiomyocyte mitochondrial function by diminishing fatty acid-mediated oxygen consumption and increasing superoxide levels. J. Mol. Cell. Cardiol. 2015, 89:360-364.